清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
加贝发布了新的文献求助10
2秒前
可靠的书桃完成签到 ,获得积分10
16秒前
同學你該吃藥了完成签到 ,获得积分10
16秒前
23秒前
羊白玉完成签到 ,获得积分10
27秒前
33秒前
sidneyyang发布了新的文献求助10
37秒前
37秒前
Arthur完成签到 ,获得积分10
1分钟前
简择两发布了新的文献求助10
1分钟前
天边的云彩完成签到 ,获得积分10
1分钟前
gwbk完成签到,获得积分10
2分钟前
cy0824完成签到 ,获得积分10
2分钟前
Vincent完成签到,获得积分10
2分钟前
南宫炽滔完成签到 ,获得积分10
2分钟前
英俊的铭应助简择两采纳,获得10
3分钟前
丘比特应助简择两采纳,获得10
3分钟前
科目三应助山河已秋采纳,获得30
3分钟前
研友_nxw2xL完成签到,获得积分10
3分钟前
所所应助yurbb采纳,获得10
3分钟前
muriel完成签到,获得积分10
3分钟前
Akim应助科研通管家采纳,获得30
3分钟前
5分钟前
yurbb发布了新的文献求助10
5分钟前
Wang完成签到 ,获得积分20
5分钟前
5分钟前
5分钟前
紫熊完成签到,获得积分10
5分钟前
5分钟前
111111完成签到,获得积分10
5分钟前
5分钟前
爱静静举报lvbowen求助涉嫌违规
5分钟前
6分钟前
金钰贝儿完成签到,获得积分10
6分钟前
6分钟前
小马甲应助成就的凡梦采纳,获得10
6分钟前
imi完成签到 ,获得积分0
6分钟前
6分钟前
6分钟前
6分钟前
高分求助中
Spray / Wall-interaction Modelling by Dimensionless Data Analysis 2000
Write Like a Chemist: A Guide and Resource (第二版) 600
Mixed-anion Compounds 600
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Earth System Geophysics 500
Aspects of Babylonian celestial divination: the lunar eclipse tablets of Enūma Anu Enlil 500
Geochemistry, 2nd Edition 地球化学经典教科书第二版 401
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3200779
求助须知:如何正确求助?哪些是违规求助? 2850531
关于积分的说明 8072248
捐赠科研通 2514267
什么是DOI,文献DOI怎么找? 1347000
科研通“疑难数据库(出版商)”最低求助积分说明 640305
邀请新用户注册赠送积分活动 610509